3F Therapeutics Inc.
This article was originally published in Start Up
3F Therapeutics Inc. is entering the valve replacement market covering all its bases: The start-up, which caters to cardiac surgeons, is making sure physicians have several options when it comes to valve replacement technology.
You may also be interested in...
Health Research International has just issued a report, "US Opportunities in Heart Valve Disease Management." According to the report, the market for valve replacement and repair products will grow from more than $500 million in 2004 to some $900 million in 2010, with the greatest growth occurring in percutaneous valve products.
Start-ups with percutaneous technologies aim to move heart valve procedures out of the OR and into the cath lab.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.